CIK 0001817713
- Large accelerated filer
Janux Therapeutics, Inc.
Sign in to watch- Ticker
- JANX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 822289112
- Phone
- +1 858-751-4493
- Business address
- 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-11 | Gujrathi Sheila Director | Grant or award · Stock Option (right to buy) | +11,667 | 11,667 | ||
| 2025-06-11 | Hernday Natasha Director | Grant or award | +3,750 | 8,731 | ||
| 2025-06-11 | Hernday Natasha Director | Grant or award · Stock Option (right to buy) | +11,667 | 11,667 | ||
| 2025-06-11 | McNulty Alana B. Director | Grant or award | +3,750 | 6,250 | ||
| 2025-06-11 | McNulty Alana B. Director | Grant or award · Stock Option (right to buy) | +11,667 | 11,667 | ||
| 2025-06-11 | Simson Jake Director | Grant or award | +3,750 | 6,250 | ||
| 2025-06-11 | Simson Jake Director | Grant or award · Stock Option (right to buy) | +11,667 | 11,667 | ||
| 2025-06-11 | Kung Winston Director | Grant or award | +3,750 | 6,250 | ||
| 2025-06-11 | Kung Winston Director | Grant or award · Stock Option (right to buy) | +11,667 | 11,667 | ||
| 2025-06-02 | Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr | Grant or award | +44,000 | 44,000 | ||
| 2025-06-02 | Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr | Grant or award · Stock option (right to buy) | +154,000 | 154,000 | ||
| 2025-05-01 | Meyer Andrew Hollman Chief Business Officer | Option exercise 10b5-1 | +3,333 | $4.21 | $14K | 85,472 |
| 2025-05-01 | Meyer Andrew Hollman Chief Business Officer | Sale 10b5-1 | −2,933 | $31.95 | $94K | 82,539 |
| 2025-05-01 | Meyer Andrew Hollman Chief Business Officer | Sale 10b5-1 | −400 | $32.60 | $13K | 82,139 |
| 2025-05-01 | Meyer Andrew Hollman Chief Business Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −3,333 | 87,332 | ||
| 2025-04-21 | Meyer Andrew Hollman Chief Business Officer | Option exercise 10b5-1 | +3,334 | $4.21 | $14K | 85,473 |
| 2025-04-21 | Meyer Andrew Hollman Chief Business Officer | Sale 10b5-1 | −3,334 | $30.00 | $100K | 82,139 |
| 2025-04-21 | Meyer Andrew Hollman Chief Business Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −3,334 | 90,665 | ||
| 2025-03-07 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +110,206 | $31.02 | $3.4M | 10,141,287 |
| 2025-03-06 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +372,093 | $30.78 | $11.5M | 10,031,081 |
Page 4 of 15 · 294 trades